Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells

Acquired tamoxifen resistance (TamR) remains a major challenge in breast cancer endocrine therapy. The mechanism of acquiring tamoxifen resistance remains elusive, and no effective drugs are available. In this investigation, we determined that the expression of the DNA damage marker γH2AX is upregul...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zheyong, Li, Wenjie, Liu, Jie, Li, Juan, He, Fang, Jiang, Yina, Yang, Lu, Li, Pingping, Wang, Bo, Wang, Yaochun, Ren, Yu, Yang, Jin, Luo, Zhijun, Vaziri, Cyrus, Liu, Peijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288718/
https://www.ncbi.nlm.nih.gov/pubmed/28150753
http://dx.doi.org/10.1038/srep41776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288718/
https://www.ncbi.nlm.nih.gov/pubmed/28150753
http://dx.doi.org/10.1038/srep41776

Ejemplares similares